Gyeonggi-do, South Korea

Won Kyu Lee

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Hedgehog, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Won Kyu Lee. Retrieved from https://idiyas.com/inventor/won-kyu-lee-93roizmq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Won Kyu Lee in Monoclonal Antibody Development

Introduction

Won Kyu Lee is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents. His work focuses on addressing critical health issues such as hypertension and cancer.

Latest Patents

Won Kyu Lee holds a patent for an "Endothelin receptor type A activity regulating antibody." This invention pertains to a monoclonal antibody or a fragment that specifically recognizes and binds to the extracellular domain of the endothelin receptor type A. The monoclonal antibody is designed for use as a therapeutic agent for conditions associated with endothelin receptor type A, including hypertension and certain types of cancer.

Career Highlights

Throughout his career, Won Kyu Lee has demonstrated a commitment to advancing medical science through innovative research. His work has the potential to impact the treatment of serious health conditions, showcasing his dedication to improving patient outcomes.

Collaborations

Won Kyu Lee has collaborated with notable colleagues, including Sang Taek Jung and Yeon Gyu Yu. These partnerships have likely contributed to the success of his research and the development of his patented inventions.

Conclusion

Won Kyu Lee's contributions to the field of monoclonal antibodies represent a significant advancement in therapeutic options for hypertension and cancer. His innovative work continues to pave the way for future research and development in biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…